Stock Ratings / Health Care / HIND / options

BOLT (38) KTTA (40) LPCN (23) BIVI (32) ⌘ Pro Terminal →

Vyome Holdings Inc. (HIND) Options Positioning, Max Pain & Unusual Sweeps

$1.80 +2.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.81

Vyome Holdings Inc. (HIND) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $12.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HIND Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HIND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Vyome Holdings Inc. (NASDAQ: HIND) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.80 (+2.86% 1D, market cap $12.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HIND ranks #887 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HIND compare to BOLT and KTTA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HIND carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 68.4%, and ROIC of -35.0%. By comparison, BOLT (Bolt Biotherapeutics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M) and KTTA (Pasithea Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, HIND leads on earnings multiple (N/A) while HIND leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HIND?

▼

Per HIND's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001427570), Vyome Holdings Inc. generated $319.7K in revenue (-96.0% YoY), -$10.3M in net income, and -$3.7M in free cash flow against $6.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.81 (+0.32%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HIND)Realized 20D OHLCV Swing Band: ±11.4%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY HIND SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 21.9% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.01-8.5% Next Q

Q2 (-2Q)

Grade E$1.84-7.1% Next Q

Q3 (-1Q)

Grade E$1.71+5.3% Next Q

Current

Grade E$1.80-9.8% Hist 90D α

Trajectory: E (37) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HIND Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HIND currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.99) and Max Pain ($1.89) forces dealer call-delta covering toward $6.89.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HIND• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HIND Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±11.4%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (HIND)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for HIND.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HIND)

✓Walkthrough of HIND's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HIND // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.88%▼ DESCENDING CHANNEL

2026-11-02O $1.72H $1.80L $1.72C $1.80VOL 13.2K

RES: $2.23SUP: $1.60SMA50: $1.99SMA200: $2.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HIND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HIND Butterfly Map → + Track HIND →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HIND today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HIND. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HIND today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HIND)

Health Care Rank #887 of 1016 ⚔️ BOLT vs HIND Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HIND vs. BOLT, KTTA, LPCN, BIVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vyome Holdings Inc. (HIND) ranks #887 by composite RQD confidence (29/100, grade E) and #876 by equity capitalization ($12.3M). Within this direct 5-issuer industry benchmark cohort, HIND leads on earnings valuation at N/A trailing P/E, while HIND leads on capital efficiency and profitability with -35.0% ROIC and 68.4% gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with HIND at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HIND ACTIVE Vyome Holdings Inc.	E	29/100	—	68.4%	-35.0%	+2.86%	$12.3M	Benchmark Subject
BOLT Bolt Biotherapeutics Inc.	D-	38/100	—	—	-35.0%	+3.62%	$12.3M	/bolt-vs-hind →
KTTA Pasithea Therapeutics Corp.	D-	40/100	—	—	-35.0%	+0.16%	$12.3M	/ktta-vs-hind →
LPCN Lipocine Inc.	E	23/100	—	—	-35.0%	-5.26%	$12.5M	/lpcn-vs-hind →
BIVI BioVie Inc. (Class A)	E	32/100	—	—	-35.0%	+3.62%	$12.0M	/bivi-vs-hind →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001427570

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vyome Holdings Inc. (HIND) reported GAAP revenue of $319.7K (-96.0% vs. FY2024 revenue of $8.0M , and -96.3% cumulative change since FY2023) , GAAP net income of -$10.3M, operating cash flow of -$3.7M, and free cash flow of -$3.7M (-510.4% YoY). On the balance sheet, HIND closed FY2025 with $6.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$319.7K	-$10.3M	-$3.7M	-$3.7M	$6.5M	—
FY2024 (FY)	2024-12-31	$8.0M	-$1.4M	-$614.1K	-$614.1K	$1.4M	—
FY2023 (FY)	2023-12-31	$8.7M	-$11.4M	-$17.0M	-$17.0M	—	—

3. HIND Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HIND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HIND compare to BOLT and KTTA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HIND?

Where is HIND trading relative to its 50-day, 200-day, and 52-week technical levels?

HIND last traded at $1.80 (+2.86% on volume of 42,214 shares), positioning the stock -9.55% below its 50-day simple moving average ($1.99) and -19.64% below its 200-day simple moving average ($2.24). Across its 52-week range of $1.62 to $6.56, HIND sits at the 3.6% percentile with a 14-day RSI of 36.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.4% ($1.59 to $2.01).

HIND Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is HIND's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for HIND.

Direct Sub-Reports: HIND RQD Cockpit HIND 12M Forecast HIND Earnings & Move HIND Dividends & DRIP HIND Insiders & 13F HIND Whale Options HIND Profit Sankey HIND News & Why

ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HIND — Vyome Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:51:17Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HIND carries an RQD Score of 29 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 8 / 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently converting capital into cash returns. Whale 13F Flow scores 3 / 20 for institutional accumulation and options positioning, and Insider Conviction scores 3 / 20 for SEC Form 4 and Congressional PTR cluster flow, both signaling weak smart-money support. Macro Regime Fit scores 7 / 20 with a Beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 8 / 20, reflecting an Altman Z of 2.5, a Piotroski F of 3/9, and Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the pillar profile points to a company where the cash engine, ownership signals, and forensic indicators all sit in weak territory simultaneously. Any upside case would need to rest on a catalyst that changes the cash-generation picture, since the current scores do not show that inflection. Valuation is difficult to anchor because trailing and forward earnings multiples are not available in source data, so the tradeoff cannot be framed against earnings. The rating is an analytical summary of the supplied data and is not personalized financial advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.3M	$-10.5M	$-10.3M	N/A	$-3.7M	$5.0M	N/A
FY 2024	$8.0M	$-1.0M	$-1.4M	N/A	$-0.6M	$0.1M	N/A
FY 2023	$8.7M	$-15.4M	$-11.4M	N/A	$-17.0M	N/A	N/A

Per the Market Data, operating margin and net margin are both -60% and gross margin is 68.4%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Revenue fell from $8.0M in FY 2024 to $0.3M in FY 2025 per the SEC financials, while net loss widened to $-10.3M, making the FY 2025 margin profile the most pressing item in the period data. Balance sheet posture is reported as cash of $5.0M against FY 2025 free cash flow of $-3.7M.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, the most material items are:

Patent progress (YELLOW): A Yahoo Finance report indicates a USPTO Notice of Allowance for a U.S. patent covering VT-1908, framed as targeting a $20+ Billion ocular inflammation market.
Leadership recognition (YELLOW): A co-founder was promoted to Professor at Harvard Medical School, per Yahoo Finance.
Conference presence (YELLOW): Investing.com reported on a Chardan healthcare conference appearance.
Risk Watch (RED): An item headlined as a Q2 2026 earnings report describes a narrower-than-expected loss that failed to lift shares; the summary field of this item is malformed and attributes content to a non-issuer domain, so its reliability should be treated cautiously.

Butterfly Supply-Chain Graph: Supply chain is NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the trailing and forward earnings multiples, given that P/E, forward P/E, EV/EBITDA, and EPS are all unavailable?
What drove the decline in revenue from $8.0M in FY 2024 to $0.3M in FY 2025, and is there a path back to revenue?
Debt is reported as N/A in every period while Debt/Equity is 0.5; what is the actual debt composition and maturity profile?
What is the cash runway given $5.0M in cash against $-3.7M of FY 2025 free cash flow?
Does the USPTO Notice of Allowance for VT-1908 have any commercialization, licensing, or partnering timeline attached to it?

HIND Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vyome Holdings Inc. (HIND) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HIND Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 2h ago

Vyome Holdings, Inc. Estimates – NASDAQ:HIND

TradingView report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 5h ago

Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School

Yahoo Finance report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 8h ago

Vyome at Chardan healthcare conference: lean biotech bets on rare wounds

Investing.com report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 11h ago

Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market

Yahoo Finance report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 14h ago

AZR Stock Price and Chart — BOATS:AZR

TradingView report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 17h ago

HIND Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares - Interim Report

https://www.dars.gov.et/ report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 20h ago

Vyome Holdings, Inc. (HIND) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HIND Bull vs. Bear Conversation Board — What's Your Call at $1.80?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HIND 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.54 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is HIND (E • RQD 29/100) a Buy at $1.75?

Welcome to the HIND (Vyome Holdings Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.44 (-17.7%)

Spot @ $1.75

Pump the brakes on HIND — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HIND, but look at what you are paying: current EV/EBITDA multiples with 68.4% gross margins. Unless Vyome Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.12 (+21.1%)

Spot @ $1.75

HIND cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HIND, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.75 (52-wk range $1.62 - $6.56), any beat on forward guidance forces shorts and underweight funds to chase.